334 related articles for article (PubMed ID: 32896613)
41. Glioblastoma precision therapy: From the bench to the clinic.
Zhou Y; Wu W; Bi H; Yang D; Zhang C
Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
[TBL] [Abstract][Full Text] [Related]
42. Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Gawley M; Almond L; Daniel S; Lastakchi S; Kaur S; Detta A; Cruickshank G; Miller R; Hingtgen S; Sheets K; McConville C
J Control Release; 2020 Aug; 324():1-16. PubMed ID: 32407745
[TBL] [Abstract][Full Text] [Related]
43. Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma.
Ravuluri JAV; Rao V; Kumar G; Manandhar S; Cheruku SP; Bisht P; Chamallmudi MR; Nandakumar K; Kumar L; Kumar N
Curr Pharm Des; 2023; 29(22):1775-1790. PubMed ID: 37403389
[TBL] [Abstract][Full Text] [Related]
44. Recent advances in brain tumor therapy: application of electrospun nanofibers.
Norouzi M
Drug Discov Today; 2018 Apr; 23(4):912-919. PubMed ID: 29499377
[TBL] [Abstract][Full Text] [Related]
45. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
46. A state-of-the-art liposome technology for glioblastoma treatment.
Hasan I; Roy S; Ehexige E; Wu R; Chen Y; Gao Z; Guo B; Chang C
Nanoscale; 2023 Nov; 15(45):18108-18138. PubMed ID: 37937394
[TBL] [Abstract][Full Text] [Related]
47. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
48. Nanostructured Therapeutic Systems of PUFAs for the Treatment of Glioblastoma Multiforme.
Saad S; Beg S; Jain GK; Ahmad FJ
Curr Drug Metab; 2021; 22(14):1087-1102. PubMed ID: 33388016
[TBL] [Abstract][Full Text] [Related]
49. Frontiers in the treatment of glioblastoma: Past, present and emerging.
Janjua TI; Rewatkar P; Ahmed-Cox A; Saeed I; Mansfeld FM; Kulshreshtha R; Kumeria T; Ziegler DS; Kavallaris M; Mazzieri R; Popat A
Adv Drug Deliv Rev; 2021 Apr; 171():108-138. PubMed ID: 33486006
[TBL] [Abstract][Full Text] [Related]
50. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
51. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
Zhang X; Ding K; Wang J; Li X; Zhao P
Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
[TBL] [Abstract][Full Text] [Related]
52. Local Drug Delivery Strategies for Glioblastoma Treatment.
Cha GD; Jung S; Choi SH; Kim DH
Brain Tumor Res Treat; 2022 Jul; 10(3):151-157. PubMed ID: 35929112
[TBL] [Abstract][Full Text] [Related]
53. Targeting glioblastoma through nano- and micro-particle-mediated immune modulation.
Poot E; Maguregui A; Brunton VG; Sieger D; Hulme AN
Bioorg Med Chem; 2022 Oct; 72():116913. PubMed ID: 36007293
[TBL] [Abstract][Full Text] [Related]
54. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.
Candolfi M; Kroeger KM; Xiong W; Liu C; Puntel M; Yagiz K; Muhammad AG; Mineharu Y; Foulad D; Wibowo M; Assi H; Baker GJ; Lowenstein PR; Castro MG
Anticancer Agents Med Chem; 2011 Oct; 11(8):729-38. PubMed ID: 21707497
[TBL] [Abstract][Full Text] [Related]
55. Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme.
Desai V; Bhushan A
Biomed Res Int; 2017; 2017():9363040. PubMed ID: 29359162
[TBL] [Abstract][Full Text] [Related]
56. Current status of intratumoral therapy for glioblastoma.
Mehta AI; Linninger A; Lesniak MS; Engelhard HH
J Neurooncol; 2015 Oct; 125(1):1-7. PubMed ID: 26233248
[TBL] [Abstract][Full Text] [Related]
57. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
[TBL] [Abstract][Full Text] [Related]
58. Nanoparticles for hyperthermic therapy: synthesis strategies and applications in glioblastoma.
Verma J; Lal S; Van Noorden CJ
Int J Nanomedicine; 2014; 9():2863-77. PubMed ID: 24959075
[TBL] [Abstract][Full Text] [Related]
59. Recent advancements and theranostics strategies in glioblastoma therapy.
Baddam SR; Kalagara S; Kuna K; Enaganti S
Biomed Mater; 2023 Aug; 18(5):. PubMed ID: 37582381
[TBL] [Abstract][Full Text] [Related]
60. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.
Persano L; Rampazzo E; Basso G; Viola G
Biochem Pharmacol; 2013 Mar; 85(5):612-622. PubMed ID: 23063412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
